Bhaskarjyoti Gogoi

Bhaskarjyoti Gogoi

Auto-generated profile, based on publicly available information

Bhaskarjyoti Gogoi

Department of Biotechnology, Royal Global University, Guwahati, India

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
JUJ. Upadhyay
J. Upadhyay
AKA. Kumar
A. Kumar
BGB. Gogoi
B. Gogoi
ABA.K. Buragohain
A.K. Buragohain

10 October 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MMMunmi Majumder
Munmi Majumder
SDShibjyoti Debnath
Shibjyoti Debnath
RGRahul L. Gajbhiye
Rahul L. Gajbhiye
RSRimpi Saikia
Rimpi Saikia
BGBhaskarjyoti Gogoi
Bhaskarjyoti Gogoi
RMRupak Mukhopadhyay
Rupak Mukhopadhyay
Medicinal plant-based therapies can be important for treatment of cancer owing to high efficiency, low cost and minimal side effects. Here, we report the anti-cancer efficacy of Ricinus communis L. fruit extract (RCFE) using estrogen positive MCF-7 and highly aggressive, triple negative MDA-MB-231 breast cancer cells. RCFE induced cytotoxicity in these cells in dose and time-dependent manner. It also demonstrated robust anti-metastatic activity as it significantly inhibited migration, adhesion, invasion and expression of matrix metalloproteinases (MMPs) 2 and 9 in both cell lines. Further, flow cytometry analysis suggested RCFE-mediated induction of apoptosis in these cells. This was supported by attenuation of anti-apoptotic Bcl-2, induction of pro-apoptotic Bax and caspase-7 expressions as well as PARP cleavage upon RCFE treatment. RCFE (0.5 mg/Kg body weight) treatment led to significant reduction in tumor volume in 4T1 syngeneic mouse model. HPLC and ESI-MS analysis of active ethyl acetate fraction of RCFE detected four compounds, Ricinine, p-Coumaric acid, Epigallocatechin and Ricinoleic acid. Individually these compounds showed cytotoxic and migration-inhibitory activities. Overall, this study for the first time demonstrates the anti-cancer efficacy of the fruit extract of common castor plant which can be proposed as a potent candidate for the treatment of breast cancer.

1 March 2018 in Pharmacological Research
Verified
Journal Article
Closed access
SSSuman Kumar Samanta
Suman Kumar Samanta
Raghuram KandimallaRaghuram Kandimalla
Raghuram Kandimalla
BGBhaskarjyoti Gogoi
Bhaskarjyoti Gogoi
KDKrishna Nayani Dutta
Krishna Nayani Dutta
PCParamita Choudhury
Paramita Choudhury
NTNarayan Chandra Talukdar
Narayan Chandra Talukdar

25 May 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
SMSaurov Mahanta
Saurov Mahanta
PCPurvita Chowdhury
Purvita Chowdhury
NGNeelutpal Gogoi
Neelutpal Gogoi
NGNabajyoti Goswami
Nabajyoti Goswami
DBDebajit Borah
Debajit Borah
BGBhaskarjyoti Gogoi
Bhaskarjyoti Gogoi
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which was first reported in Wuhan province of China, has become a deadly pandemic causing alarmingly high morbidity and mortality. In the absence of new targeted drugs and vaccines against SARS-CoV-2 at present, the choices for effective treatments are limited. Therefore, considering the exigency of the situation, we focused on identifying the available approved drugs as potential inhibitor against the promising Coronavirus drug target, the Main Protease, using computer-aided methods. We created a library of U. S. Food and Drug Administration approved anti-microbial drugs and virtually screened it against the available crystal structures of Main Protease of the virus. The study revealed that Viomycin showed the highest -CDocker energy after docking at the active site of SARS-CoV-2 Main Protease. It is noteworthy that Viomycin showed higher -CDocker energy as compared to the drugs currently under clinical trial for SARS-CoV-2 treatment viz. Ritonavir and Lopinavir. Additionally, Viomycin formed higher number of H-bonds with SARS-CoV-2 Main Protease than its co-crystallised inhibitor compound N3. Molecular dynamics simulation further showed that Viomycin embedded deeply inside the binding pocket and formed robust binding with SARS-CoV-2 Main Protease. Therefore, we propose that Viomycin may act as a potential inhibitor of the Main Protease of SARS-CoV-2. Further optimisations with the drug may support the much-needed rapid response to mitigate the pandemic. Communicated by Ramaswamy H. Sarma

25 November 2020 in Molecular Diversity
Verified
Journal Article
Closed access
PDF file
NGNeelutpal Gogoi
Neelutpal Gogoi
PCPurvita Chowdhury
Purvita Chowdhury
AGAshis Kumar Goswami
Ashis Kumar Goswami
ADAparoop Das
Aparoop Das
DCDipak Chetia
Dipak Chetia
BGBhaskarjyoti Gogoi
Bhaskarjyoti Gogoi

1 August 2018 in Biochimie
Verified
Journal Article
Closed access
DBDipanjan Banerjee
Dipanjan Banerjee
ASArchana Sinha
Archana Sinha
SSSudeshna Saikia
Sudeshna Saikia
BGBhaskarjyoti Gogoi
Bhaskarjyoti Gogoi
ARArvind K. Rathore
Arvind K. Rathore
SDSuman Dasgupta
Suman Dasgupta